Cote d'Ivoire vs Mauritania: Treatment coverage for schistosomiasis

Cote d'Ivoire
27.2%
in 2024
Mauritania
12.6%
in 2024
Cote d'Ivoire rank
38th
Mauritania rank
40th

Treatment coverage for schistosomiasis over time

  • Cote d'Ivoire
  • Mauritania
020406080200720152024

How they compare

Cote d'Ivoire currently reports 27.2% against 12.6% in Mauritania, a difference of 14.6%.

That makes Cote d'Ivoire's figure about 2.2 times Mauritania's.

The two have swapped places 5 times across 10 shared years of data; in 2012 it was Mauritania ahead.

Cote d'Ivoire ranks 38th and Mauritania ranks 40th of 45 countries.

Cote d'Ivoire has averaged higher in every one of the 2 decades both report.

Head to head by decade

Decade Cote d'Ivoire Mauritania Difference Ahead
2010s 35.6% 23.8% 11.8% Cote d'Ivoire
2020s 51.6% 29.4% 22.1% Cote d'Ivoire

Averages of every year both report within each decade.

Frequently asked questions

Which has higher treatment coverage for schistosomiasis, Cote d'Ivoire or Mauritania?
Cote d'Ivoire, at 27.2% against 12.6% in Mauritania as of 2024.
What is the difference in treatment coverage for schistosomiasis between Cote d'Ivoire and Mauritania?
14.6%, with Cote d'Ivoire ahead.
How many years of comparable data are there for Cote d'Ivoire and Mauritania?
10 years are reported by both, from 2012 to 2024.
How do Cote d'Ivoire and Mauritania rank globally for treatment coverage for schistosomiasis?
Cote d'Ivoire ranks 38th and Mauritania ranks 40th of 45 countries.
Where does this data come from?
World Health Organization (2025) – with minor processing by Our World in Data, published as Treatment coverage for schistosomiasis. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Treatment coverage for schistosomiasis
Unit
%
Source
World Health Organization (2025) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
45 places, 573 data points, 2006–2024
Last refreshed

Drug coverage out of estimated population who require it.